INTRODUCTION
============

Beckwith-Wiedemann syndrome (BWS; MIM 130650) is a complex congenital overgrowth disorder that occurs in approximately 1/13,700 live births. A diagnosis of BWS is usually based on the presence of two out of five major characteristics in the infant: macrosomia (birth weight \>97th percentile), macroglossia, neonatal hypoglycaemia, ear creases or pits and/or abdominal wall defects. BWS can include other features such as hemihypertrophy, visceromegaly, hepatoblastoma, embryonal tumours, nevus flammeus, cleft palate, cardiac abnormalities, advanced bone age, enlarged placenta and abnormalities in placental vasculature ([@b56-0040814]). There is a high incidence of premature birth for BWS infants, sometimes in combination with polyhydramnios and gestational hypertension ([@b54-0040814]), with some BWS mother's suffering the more serious complication of HELLP and preeclampsia ([@b42-0040814]).

BWS patients display multiple genetic and epigenetic mutations that mainly disrupt the expression of a cluster of imprinted genes located at human chromosome 11p15 ([@b11-0040814]; [@b55-0040814]). Nearly half of patients with familial BWS carry germline mutations in the coding sequence of the maternally expressed cyclin-dependent kinase inhibitor 1c (*CDKN1C; p57^KIP2^*) gene ([@b23-0040814]; [@b24-0040814]; [@b31-0040814]; [@b37-0040814]; [@b16-0040814]). However, BWS is predominantly seen as a sporadic occurrence and, in this group of patients, direct DNA mutations within *CDKN1C* mutations are relatively infrequent (\<5%) ([@b11-0040814]). The most frequent alteration in BWS, reported in \>50% of patients, is loss of DNA methylation at the promoter of a long, non-coding RNA, *KCNQ1OT* (also known as *LIT1*), which lies 220 kb distant to *CDKN1C.* Loss of methylation of this region is associated with downregulation of *CDKN1C* ([@b13-0040814]). Studies on the corresponding mouse imprinted domain on distal chromosome 7 demonstrate that this region, termed *KvDMR1* or IC2 (imprinting centre 2), acts as the imprinting centre for *Cdkn1c* ([@b7-0040814]; [@b17-0040814]; [@b18-0040814]). All these data suggest that loss of *CDKN1C* is a factor in the majority of BWS cases. However, although three independent studies examining loss of *Cdkn1c* function in mice identified several developmental abnormalities consistent with BWS, including abdominal wall defects, cleft palate, placentomegaly, renal dysplasia, adrenal cytomegaly, maternal preeclampsia and prematurity, none reported the cardinal feature of BWS, that of somatic overgrowth at birth ([@b58-0040814]; [@b60-0040814]; [@b49-0040814]; [@b50-0040814]; [@b29-0040814]).

In mice, *Cdkn1c* is expressed in derivatives of all three germ layers -- the endoderm, mesoderm and ectoderm -- and in all major organs of the body during embryonic development ([@b30-0040814]; [@b34-0040814]; [@b57-0040814]). *Cdkn1c* is primarily expressed in cells that are exiting cell cycle but are not terminally differentiated. In extraembryonic tissues, *Cdkn1c* is dynamically expressed during mid-to-late placental development in the giant trophoblast cells that abut the maternal decidua, the glycogen cells within the junctional zone, the fetal endothelium, the syncytiotrophoblast and some larger sinusoidal nuclei ([@b41-0040814]; [@b57-0040814]; [@b20-0040814]; [@b10-0040814]). The spatial and temporal expression profile of *Cdkn1c* probably reflects the multiple functional roles that *Cdkn1c* plays during development. *Cdkn1c*, also known as *p57^Kip2^*, encodes a cyclin-dependant kinase inhibitor (CDKi) belonging to the same family as *Cdkn1a* (encoding p21) and *Cdkn1b* (encoding p27) ([@b22-0040814]; [@b30-0040814]; [@b34-0040814]; [@b35-0040814]). As with all CDKis, excess *Cdkn1c* induces cell cycle arrest ([@b30-0040814]; [@b34-0040814]). In addition, *Cdkn1c* also directs differentiation in some cell types ([@b15-0040814]; [@b40-0040814]; [@b27-0040814]; [@b28-0040814]), influences cell migration ([@b43-0040814]; [@b25-0040814]) and modifies the actin cytoskeleton ([@b59-0040814]; Vlachos and [@b28-0040814]). CDKN1C therefore functions in numerous processes to ensure correct development.

We have previously demonstrated that early embryonic growth is exquisitely sensitive to the precise dosage of *Cdkn1c* on the inbred mouse strain background 129S2/SvHsd (129) ([@b1-0040814]). Mice that expressed *Cdkn1c* at just twofold the normal endogenous level were growth restricted from embryonic day 13.5 (E13.5), whereas mice deficient for *Cdkn1c* were heavier at E13.5. Several groups have reported that *Cdkn1c* deficiency does not result in an overgrowth phenotype at birth ([@b58-0040814]; [@b60-0040814]; [@b49-0040814]; [@b50-0040814]; [@b29-0040814]). These studies were performed with the isogenic mouse strain C57BL/6 (BL6). Consequently, there are two possible explanations for the absence of overgrowth reported in *Cdkn1c* mutant mice. Either there are differences in strain background that account for a disparity in growth data between different studies, or *Cdkn1c* mutant mice experience a loss of growth potential late in development. The purpose of this study was to differentiate between these two possibilities by examining the growth potential of *Cdkn1c* mutants from E15.5 until birth on a pure (\>99%) 129 strain background.

RESULTS
=======

Characterising newborn *Cdkn1c* mutant (loss of maternal allele) phenotype on the 129 strain background
-------------------------------------------------------------------------------------------------------

On a predominantly BL6 strain background, the majority of *Cdkn1c* mutant pups die around the time of birth ([@b58-0040814]; [@b60-0040814]; [@b49-0040814]). We found that the survival frequency of *Cdkn1c* mutant pups on the 129 background was similar to this, with four out of 60 survivors carrying the targeted allele ([Table 1](#t1-0040814){ref-type="table"}). To determine newborn weights, a total of 130 pups were recovered at birth from 22 litters. Similar to previous studies, newborn *Cdkn1c* mutant pups were not heavier than wild-type littermates ([Fig. 1A](#f1-0040814){ref-type="fig"}). Typically, recovered wild-type pups had suckled (55/84), whereas only 4/46 (11.5%) *Cdkn1c* mutant pups showed evidence of milk in their stomach ([Fig. 1B](#f1-0040814){ref-type="fig"}). *Cdkn1c* mutant pups displayed phenotypes that have previously been reported for the BL6 background, with various levels of limb shortening, cleft palate, abdominal muscle abnormalities and air inflated abdomens (data not shown). Cleft palate was not present in the four mutants that fed but the absence of overgrowth in *Cdkn1c* mutant pups could not be explained by a failure to suckle because, when fed animals were excluded from the analysis, mutants were still not significantly heavier than wild-type littermates ([Fig. 1C](#f1-0040814){ref-type="fig"}). Thus, as with the BL6 studies, *Cdkn1c* mutant mice were not overgrown at birth on the 129 strain background.

###### 

Survival data for *Cdkn1c* mutants on a 129 strain background

![](DMM007328T1)

![**Growth trajectory of *Cdkn1c*^129^ mutants.** (A) Postnatal weights for wild-type (WT) and *Cdkn1c* mutant pups on a pure 129 background (WT, 1561±167 mg, *n*=84; *Cdkn1c^−m/+p^*, 1586±185 mg, *n*=46; 22 litters; *P=*0.44). Error bars show standard deviation. (B) Number of wild-type compared with mutant newborns that showed evidence of suckling. (C) Postnatal weights for wild-type and *Cdkn1c* mutant pups after excluding data from fed animals (WT, 1510±296 mg, *n*=29 versus *Cdkn1c^−m/+p^* 1567±287 mg, *n*=42; *P*=0.132). (D,E) Embryonic weights for wild type and *Cdkn1c* mutant at (D) E15.5 (WT, 407±84 mg, *n*=24; *Cdkn1c^−m/+p^*, 468±113 mg, *n*=21; *P*=6.27×10^−6^) and (E) E18.5 (WT, 1196±129 mg, *n*=63; *Cdkn1c^−m/+p^*, 1169±169, *n*=63; *P*=0.001).](DMM007328F1){#f1-0040814}

In order to identify the time point after E13.5 at which *Cdkn1c* mutant embryonic growth was constrained, weights were examined at E15.5 and E18.5. In contrast to immediately after birth, there was no evidence for loss of viability at these earlier stages ([Table 1](#t1-0040814){ref-type="table"}), but *Cdkn1c* mutant embryos were 15% heavier than wild-type embryos at E15.5 (*P*=6.28×10^−6^) and 8% heavier at E18.5 (*P*=0.001) ([Fig. 1D,E](#f1-0040814){ref-type="fig"}). This work identified a slowdown in embryonic growth very late in gestation.

Defects in the trilaminar trophoblast cell structure that separates the maternal blood sinusoids from the fetal capillaries
---------------------------------------------------------------------------------------------------------------------------

Loss of growth potential late in gestation is a classic indicator of placental insufficiency. The previously reported characteristics of the *Cdkn1c* mutant placenta include overgrowth with overproliferation of trophoblast cells, reduced vascularisation of the labyrinth zone and reduced diameter of mutant fetal capillaries, suggesting impaired function ([@b61-0040814]; [@b49-0040814]). Similarly, *Cdkn1c* mutant 129 placentas were substantially overgrown ([Fig. 2A](#f2-0040814){ref-type="fig"}). Examination of the *Cdkn1c* mutant 129 placentas additionally exposed substantial areas of pooled maternal blood in the labyrinth at E15.5 and, more dramatically, at E18.5 in all samples examined ([Fig. 2B](#f2-0040814){ref-type="fig"}), with extensive collagen deposition adjacent to these areas in mutants but not wild-type control placentas ([Fig. 2C](#f2-0040814){ref-type="fig"}). The presence of these substantial thrombotic lesions precluded a meaningful quantification of the maternal sinusoids, but a general and irregular dilation was revealed by membrane-localised E*-*cadherin immunostaining ([Fig. 2D](#f2-0040814){ref-type="fig"}). Furthermore, the large, polyploid nuclei that normally line the maternal blood spaces at E18.5 ([@b9-0040814]) were discernible in the labyrinth of both wild-type and mutant placenta at E18.5 but there were relatively fewer in the mutant labyrinth ([Fig. 2F](#f2-0040814){ref-type="fig"}; [Table 2](#t2-0040814){ref-type="table"}).

![**Maternal blood space defect in *Cdkn1c* mutant placentas.** (A) Wet weights for wild-type (WT) and *Cdkn1c* mutant placentas on a pure 129 background at the indicated gestational stages. *Cdkn1c* mutant placentas are 46% heavier at E13.5 (WT, 52±11 mg, *n*=8; *Cdkn1c^−m/+p^*, 76±9 mg, *n*=9; *P=*0.0001), 48% heavier at E15.5 (WT, 74±16 mg, *n*=24; *Cdkn1c^−m/+p^*, 110±25 mg, *n*=21; *P=*8.86×10^−7^) and 51% heavier at E18.5 (WT, 80±24 mg, *n*=24; *Cdkn1c^−m/+p^*, 117±24 mg, *n*=24; *P=*2.37×10^−7^). (B) Haematoxylin and eosin staining of *Cdkn1c* mutant and wild-type midline representative placental sections at E18.5, as indicated. Jz, junctional zone; Lab, labyrinth; mbs, maternal blood spaces. (C) Masson's trichrome staining of *Cdkn1c* mutant and wild-type midline placental sections at E18.5. Collagen fibres stain blue (arrow). (D) E18.5 sections stained for E-cadherin followed by haematoxylin, revealing disordered maternal sinusoids in the labyrinth. (E) Higher power images of the labyrinth stained with DAPI. Large polyploid nuclei are readily apparent in wild-type but not mutant placenta.](DMM007328F2){#f2-0040814}

###### 

Relative proportion of diploid to giant nuclei in the labyrinth at E18.5
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Greatly enlarged maternal blood sinuses have previously been reported in mutant placenta lacking *Cdkn1c* in combination with excess expression of *Igf2* ([@b8-0040814]), and in placenta carrying a paternal duplication of distal chromosome 7 ([@b39-0040814]), but not in those with isolated loss of *Cdkn1c*. On the 129 strain, the maternal blood spaces defect arose from isolated loss of *Cdkn1c*. This was not explained by changes in *Igf2* and *Igf1r* mRNA levels in mutant placenta or differences in *Igf2* expression between BL6 and 129 placenta (data not shown) but probably reflects inherent differences in the structure of the placenta between the BL6 and 129 strains ([@b12-0040814]).

A study of key markers of placental development at E15.5, when the placental phenotype was well established, revealed significant reductions in the expression level of genes that are either required for, or primarily expressed in, the junctional zone of the placenta ([Fig. 3A](#f3-0040814){ref-type="fig"}). This included markers specific to spongiotrophoblast cells (*Prl8a8* and *Prl3a1*), markers expressed in both spongiotrophoblast and glycogen cells (*Tpbpa*), markers expressed in both spongiotrophoblast and giant cells (*Hand1*) and *Flt1*, which is expressed in spongiotrophoblast, fetal endothelial cells and maternal endothelial cells at this time point ([@b32-0040814]; [@b5-0040814]; [@b41-0040814]; [@b47-0040814]) ([Fig. 3A](#f3-0040814){ref-type="fig"}). By contrast, and despite the obvious abnormalities, the majority of markers assayed for the labyrinth were expressed at levels similar to wild type ([Fig. 3B](#f3-0040814){ref-type="fig"}). The exceptions were cathepsin Q (*Ctsq*), an exclusive marker of the sinusoidal trophoblast giant cells ([@b46-0040814]), whose expression was reduced to 60% of the wild-type level (*P*\<0.014), and *Prl3b1*, a marker of spongiotrophoblast cells, parietal giant trophoblast cells and sinusoidal giant trophoblast cells ([@b47-0040814]), whose expression was reduced to 48% of the wild-type level. In situ characterisation with *Prl3b1* at E15.5 suggested a defect in the sinusoidal trophoblast giant cell population ([Fig. 3C](#f3-0040814){ref-type="fig"}).

Depleted glycogen stores in mutant placenta
-------------------------------------------

It has been proposed that *Cdkn1c* might be required for the progression of pre-glycogen cells to mature glycogen cells by inhibiting their proliferation and promoting differentiation ([@b10-0040814]). Loss of function of *Cdkn1c* might consequently result in either an expansion of this cell population (overproliferation), with increased glycogen storage, or a failure in differentiation, with diminished glycogen storage. Quantification at E15.5 of the mRNAs of two genes expressed exclusively in the glycogen cells of the mouse placenta \[protocadherin 12 (*Pcdh12*) and gap junction protein, beta 3 (*Gjb3*; also known as *Cx31*)\] ([@b4-0040814]; [@b62-0040814]) revealed no difference in the expression of *Pcdh12* ([Fig. 4A](#f4-0040814){ref-type="fig"}), an early marker of this lineage ([@b4-0040814]), suggesting that *Cdkn1c* was not absolutely required for proliferation. However, expression of *Gjb3*, an exclusive marker of mature glycogen cells ([@b10-0040814]), was diminished significantly, suggesting that the differentiation of this population was affected by loss of *Cdkn1c.* Using periodic acid Schiff (PAS), a glycogen-specific stain, we observed a lower intensity of glycogen staining in placentas from mutant mice compared with controls at E15.5 ([Fig. 4B](#f4-0040814){ref-type="fig"}). The concentration of glycogen in mutant placentas was significantly lower than in controls at E15.5 (69%) and at E18.5 (62%) ([Fig. 4C](#f4-0040814){ref-type="fig"}). Defective glycogen storage might therefore contribute to the loss of embryonic growth potential very late in gestation.

![**Relative expression levels of representative placental markers at E15.5.** (A) Junctional zone markers. Achaete-scute complex homolog 2 (*Ascl2*) is required for spongiotrophoblast differentiation ([@b21-0040814]). Trophoblast specific protein-α (*Tpbpa*) is expressed in spongiotrophoblast and glycogen cells ([@b32-0040814]). Heart and neural crest derivatives expressed transcript 1 (*Hand1*) expressed in spongiotrophoblast cells and giant cells, including sinusoidal trophoblast giant cells ([@b41-0040814]; [@b47-0040814]). Prolactin family 8, subfamily a, member 8 (*Prl8a8*) and *Prl3a1* are spongiotrophoblast-cell-specific markers ([@b47-0040814]). FMS-like tyrosine kinase 1 (*Flt1*) is expressed in spongiotrophoblast cells, and fetal and maternal endothelial cells ([@b5-0040814]). \**P*=0.014. (B) Labyrinth zone markers with schematic illustrating the organisation of the trilaminar trophoblast layer with gene expression markers. *Dlx3* is expressed broadly in the labyrinth without indication of layer-specificity at E14.5 ([@b47-0040814]). Kinase insert domain protein receptor (*Kdr*; also known as *Flk1*) is expressed in fetal endothelial cells with a key role in vascular development ([@b44-0040814]). Glial cell missing *1* (*Gcm1*) encodes a transcription factor required for the initiation of fetal blood vessel branching ([@b2-0040814]) and is expressed specifically in syncytiotrophoblast II cell layer by E14.5 ([@b47-0040814]). Pleckstrin homology-like domain, family A, member 2 (*Phlda2*) is expressed in syncytiotrophoblast layers I and II ([@b38-0040814]; [@b19-0040814]; [@b14-0040814]). *Syna* is expressed in syncytiotrophoblast layer I ([@b47-0040814]). Placental lactogen II (*Prl3b1*) is expressed in both the parietal giant cell layer and sinusoidal trophoblast cells of the labyrinth ([@b26-0040814]). Cathepsin Q (*Ctsq*) is expressed exclusively in the sinusoidal trophoblast giant cells ([@b46-0040814]). Solute carrier family 2, member A1 (*Slc22a1*) is expressed both in the junctional zone and the labyrinth zone, and *Sc22a3* expression is restricted to the sinusoidal trophoblast cells ([@b45-0040814]). *\*P*=0.014. Data expressed as relative fold change in comparison with wild type. *n*=4+4. Error bars show standard deviation. (C) In situ hybridisation with *Prl3b1* riboprobe of wild-type and *Cdkn1c* mutant placental sections at E15.5. Lower magnification images (4×) illustrate diminished staining in regions containing spongiotrophoblast cells and parietal and sinusoidal giant trophoblast cells, all of which are cell types that express this marker. Higher magnification (10×) specifically illustrates *Prl3b1* staining of sinusoidal giant trophoblast cells in wild-type and mutant labyrinth.](DMM007328F3){#f3-0040814}

Overgrowth of mutants in small litters
--------------------------------------

There is a long established inverse correlation between litter size and the weight of individual pups within a litter, which suggests intrauterine competition for a limited supply of maternal resources ([@b36-0040814]). Because a functionally defective placenta might be expected to diminish the ability of an embryo to solicit nutrients from the mother, we investigated whether there was evidence for this by examining fetal weights in litters with few pups (three to five), in which intrauterine competition would be lower, versus larger litters (\>five pups), in which intrauterine competition would be greater ([Fig. 5](#f5-0040814){ref-type="fig"}). *Cdkn1c* mutant embryos were more overgrown, by 19%, in smaller litters ([Fig. 5](#f5-0040814){ref-type="fig"}). Furthermore, we did not find the anticipated inverse correlation between litter size and the weight in wild-type embryos, which were a similar average weight irrespective of litter size. This suggested that the mutants bore the brunt of increased intrauterine competition and thus might explain why *Cdkn1c* mutant mice, unlike singleton BWS babies with loss of function of *CDKN1C*, are not overgrown at birth.

![**Glycogen levels in *Cdkn1c* mutants.** (A) Relative expression levels of glycogen-cell-specific marker genes at E15.5. *\*P*=0.014. Data expressed as relative fold change in comparison with wild type. *n*=4+4. Error bars show standard deviation. (B) Periodic acid Schiff staining of *Cdkn1c* mutant and wild-type midline placental sections at E15.5 and E18.5 reveals reduced glycogen staining in the transgenic junctional zone in mutants. (C) Direct biochemical determination of stored glycogen at E15.5 and E18.5 expressed per gram placental weight.](DMM007328F4){#f4-0040814}

![***Cdkn1c* mutant embryos are able to reach their intrinsic growth potential when intrauterine competition is low.** Embryonic weights for pups in litters with three to five pups versus litters of six or more pups. Mutant pups from litters with three to five pups were 119% the weight of wild type (1314±166 mg versus 1102±151 mg; six litters; *P*=0.002 by Student's *t*-test), whereas the mutants from litters of six or more pups were 107% the weight of wild type (1095±105 mg versus 1156±158 mg; 15 litters; *P*=0.016). The weights of mutants in smaller litters were significantly different to the weights of mutants in larger litters (*P*\<0.05 by ANOVA, Tukey-Kramer post hoc test), whereas wild-type weights did not differ between litter sizes (*P*\>0.05).](DMM007328F5){#f5-0040814}

DISCUSSION
==========

The key finding of this study is that embryos deficient for *Cdkn1c* are nearly 20% heavier than their wild-type counterparts. Thus, loss of function of *CDKN1C* can result in somatic overgrowth in both humans and mice. However, in mice, overgrowth was attenuated by intrauterine competition. We also observed several striking defects of the placenta, suggesting that, despite its increased size, the function of this organ was compromised, which is consistent with the loss of growth potential of mutant embryos very late in gestation.

*Cdkn1c* mutant embryos were overgrown at E15.5 and at E18.5, just prior to birth, but, as with earlier studies, we observed no difference in the weight of mutant and wild-type pups after birth. Although this loss of growth potential might reflect developmental abnormalities of the mutant embryo, placental dysfunction provides an explanation both for the loss of growth potential late in gestation and the differences in growth potential of mutants in small litters to those in larger litters, in which there is more intrauterine competition via the placenta for maternal resources. Consistent with this interpretation, severe placental abnormalities preceded the attenuated overgrowth of *Cdkn1c* mutant mice. In particular, maternal blood seemed to be haemorrhaging into the mutant placenta, indicating a breakdown in the integrity of the trilaminar trophoblast layer that separates this maternal blood from the fetal circulation. This layer consists of three differentiated trophoblast cell types that are thought to arise from distinct precursors ([@b48-0040814]). Expression of *Ctsq* and *Prl3b1*, markers of the sinusoidal trophoblast giant cells that line the maternal sinusoids, was significantly reduced, suggesting a specific defect in this component of the trilaminar trophoblast layer. Large nuclei have been observed in these cells very late in gestation and are thought to result from endoreduplication ([@b9-0040814]). *Cdkn1c* has a known role in triggering endoreduplication in trophoblast stem (TS) cells through inhibition of Cdk1 ([@b52-0040814]). There were fewer giant cells in the labyrinth of the mutant placenta, providing the first in vivo evidence that the process of endoreduplication in the sinusoidal giant trophoblast cells is regulated by *Cdkn1c*, being delayed or diminished in mutants lacking this protein.

In addition to the obvious defect in the maternal-fetal interface, we identified a reduction in the amount of glycogen stored in the placenta at E15.5 and E18.5. Although the glycogen cell lineage was present in both wild-type and mutant placenta, diminished expression of *Gjb3*, which marks mature glycogen cells, in the mutants suggested a role for *Cdkn1c* in the maturation of these cells, which might account for their lower glycogen content. Placental glycogen stored in the late gestational placenta is thought to provide a rapidly mobilisable energy depot for the final stages of gestation, when the fetus is placing the highest demands on maternal resources for growth ([@b10-0040814]). Our data indicate that loss of function of *Cdkn1c* alone does not boost glycogen stores to match placental overgrowth and the intrinsic growth potential of the embryo. This mismatch might contribute to the failure of *Cdkn1c* mutants to attain their maximum intrinsic growth potential. We have previously shown that an adjacent imprinted gene, *Phlda2*, regulates the storage of glycogen in the placenta, and we suggested that imprinting *Cdkn1c* and *Phlda2* would have a synergistic outcome for in utero growth with the reduced dosage of *Cdkn1c* acting intrinsically to increase the fetal size and the reduced dosage of *Phlda2* providing the necessary placental modifications to support this enhanced growth ([@b51-0040814]). In this respect, it will be interesting to determine the consequences of combined loss of expression of *Cdkn1c* and *Phlda2* on late fetal growth.

The placental defects that we have observed and the unusual growth dynamics of *Cdkn1c* mutant embryos suggest an explanation for why it has been difficult to precisely replicate BWS in this animal model. First, there are comparative differences between the human and mouse placenta: the human placenta has a hemomonochorial structure lacking a cell type equivalent to the sinusoidal giant trophoblast cell in mice ([@b20-0040814]; [@b6-0040814]), so the consequence of loss of function of *CDKN1C* in the human placenta might differ from that in the mouse. More importantly, in mice there is competition between individual foetuses for maternal resources. In the mouse model, mutants were able to overgrow by 19% in small litters but were only able to overgrow by 7% in the larger litters, whereas there was no difference in the growth of the wild-type embryos with respect to intrauterine competition, indicating that mutants were less able to compete than their wild-type littermates. Human pregnancies are generally singleton; therefore, the consequences of placental dysfunction might be less apparent in some pregnancies. In twin pregnancies, there is competition between fetuses and, in a study on pregnancies in which twins were discordant for BWS, in 7/11 cases the BWS twin was not heavier than the unaffected twin ([@b3-0040814]), suggesting that the BWS fetus might experience a loss of growth potential when in competition with an unaffected fetus in utero.

Conclusions
-----------

BWS is traditionally regarded as an overgrowth disorder, with babies classified primarily on the basis of birth weight over the 97th percentile. Our data provides further support for the role of *CDKN1C* in this disorder but also suggests that, in some circumstances, BWS infants with inactivating mutations at *CDKN1C* might not display overt overgrowth at birth. Reassessing the birth weights in existing BWS patients with known inactivating mutations in *CDKN1C* and those that have an epigenetic mutation at *KvDMR* (balanced loss of expression of *CDKN1C* and *PHLDA2*) will be an important step forward in our understanding of the aetiology of BWS. This work will be important because some BWS infants might not be identified by clinicians as classic BWS cases owing to the lack of somatic overgrowth. Moreover, it might be that loss of function of *CDKN1C* is a more common mutation than currently realised, for example, in cases of cleft palate or abdominal wall defects in the absence of fetal overgrowth and in cases in which the mother develops preeclampsia.

METHODS
=======

Mice
----

The mutant mice used in this study (*Cdkn1c*^tm1Sje^), which were generated by targeted removal of exons 1 and 2 of the *Cdkn1c* gene, have been described previously ([@b60-0040814]). To avoid ambiguity, we indicate the parental origin of the alleles in heterozygotes by a superscript *m* for maternal or *p* for paternal. Male *Cdkn1c^+m/−p^* heterozygotes (absence of paternal allele; regarded as phenotypically wild type) were crossed to wild-type 129S2/SvHsd (129) females for \>12 generations and the offspring genotyped as described previously ([@b1-0040814]). To generate offspring without expression from the maternal allele (*Cdkn1c^−m/+p^*; termed *Cdkn1c* mutants), female *Cdkn1c^+m/−p^* heterozygotes were mated with wild-type 129 males.

Growth analysis
---------------

Embryonic and placental wet weights were taken at the stated time points after a discernible plug. Embryos and placentas were dissected free from extraembryonic membranes, immersed in cold fixative, briefly mopped dry and weighed. In order to obtain postnatal weights, pregnant females were monitored from E17.5. Litters were collected as found.

Histological analyses
---------------------

Placentas were fixed overnight in phosphate-buffered 4% paraformaldehyde (PFA), paraffin-embedded and 10 μm sections taken. Haematoxylin and eosin (H&E) staining, in situ hybridisation and periodic acid Schiff staining for glycogen were performed as described ([@b51-0040814]). Masson's trichrome staining was performed using a standard protocol with the substitution of light green for aniline blue, staining collagen green. E-cadherin immunohistochemistry was performed on 5 μm midline placental sections. Sections were dewaxed in xylene and rehydrated through a series of ethanol washes. Antigen retrieval was performed by boiling slides in citrate buffer (Dako) for 20 minutes. Slides were blocked in Envision+ peroxidase block (Dako) and then 10% normal rabbit serum. Slides were incubated overnight at 4°C with a 1:150 dilution of purified mouse anti E-cadherin primary antibody (BD Transduction Laboratories). Sections were incubated in anti-mouse HRP-polymer secondary antibody (Dako), and positivity observed by incubating with DAB chromogen (Dako). Slides were counterstained with Mayer's haematoxylin (Sigma), dehydrated and mounted in DPX. Slides were similarly processed without the primary antibody as controls for non-specific staining. Counting of placental cells was performed on morphologically equivalent areas of the labyrinth at E18.5. Owing to the irregularities of the maternal blood spaces, it was not feasible to determine the cell number per placenta. Instead, a count was made of the giant trophoblast cells as a proportion of the diploid trophoblast cells within a fixed field of view.

mRNA analysis
-------------

Quantitative PCR of reverse transcribed RNA was performed as described ([@b51-0040814]). *n*=4 wild type + 4 *Cdkn1c* mutant, obtained from two litters (2+2 for each litter).

Biochemical determination of placental glycogen concentration
-------------------------------------------------------------

Glycogen was extracted from whole placenta according to the method of Lo et al. ([@b33-0040814]) and resuspended in 1 ml of H~2~O. Glycogen extract was diluted 1:60 in H~2~O and glycogen concentration determined using a glycogen assay kit (BioAssay Systems) as described ([@b51-0040814]).

Statistical analyses
--------------------

Fold change in expression was calculated, using ddCt values, for each gene compared with two housekeeping genes for 4+4 samples. Mann-Whitney tests were used to determine whether these fold changes were significantly different from 1. Within litters, statistical significance \[probability (*P*) values\] was determined using the Student's *t*-test (two-tailed distribution and two sample unequal variance). To compare weight data between litters, Anderson-Darling was used as a basic test for normality (*P*=0.239) and Bartlett's test as a test for unequal variance (*P*=0.350). The Tukey-Kramer method was used in conjunction with an ANOVA to find which means were significantly different from one another. The difference between mutants and wild type in small litters and also between mutants in small litters versus mutants in large litters were both significant (*P*\<0.05), whereas the difference between mutants and wild type within the larger litters was not significant (although this was significant by a standard *t*-test), nor was the difference between wild type in small litters and those in large litters significant. The χ^2^ test was performed to determine the significance in the difference between observed over the expected appearance of a particular genotype.

###### TRANSLATIONAL IMPACT

### Clinical issue

Beckwith-Wiedemann syndrome (BWS), which affects 1/13,700 live births, is a congenital disorder causing large body size, large organs and a number of other symptoms. However, mouse models based on the most common mutation reported in BWS patients, loss of function of the cell cycle inhibitor CDKN1C, do not display overgrowth at birth, calling into question the validity of the mouse as an appropriate model organism for studying this disorder.

### Results

In this paper, the authors re-examine the CDKN1C-deficient mouse model. They find that mutants do in fact display significant overgrowth early on in gestation, but that embryonic growth slows down shortly before birth. The extent of overgrowth noted at birth is inversely proportional to the size of the litter, owing to CDKN1C-specific placental defects that constrain overgrowth in large litters.

### Implications and future directions

These findings confirm that loss of CDKN1C function causes somatic overgrowth in mice, modelling this key aspect of BWS. This has previously been masked by placental defects that constrain overgrowth when there are multiple foetuses, as is normal for mice, but not as common in humans. This finding might be of great importance for human BWS, because human BWS patients also present with placental defects. It is possible that, in some instances, such as in twin pregnancies, overgrowth of human CDKN1C mutant foetuses might be restrained, similar to what is observed in the mouse. Consequently, BWS and CDKN1C loss of function might be substantially underdiagnosed because the main diagnostic indicator is lost.
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